Zobrazeno 1 - 10
of 40
pro vyhledávání: '"AKIHIRO HAMADA"'
Autor:
Kimihiko Masui, Naoto Kume, Megumi Nakao, Toshihiro Magaribuchi, Akihiro Hamada, Takashi Kobayashi, Atsuro Sawada
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In robot-assisted surgery, in which haptics should be absent, surgeons experience haptics-like sensations as “pseudo-haptic feedback”. As surgeons who routinely perform robot-assisted laparoscopic surgery, we wondered if we could make th
Externí odkaz:
https://doaj.org/article/bd5d63361b694e129bf02fa01ba0df72
Autor:
TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI, TAKASHI KOBAYASHI
Publikováno v:
Anticancer Research. 43:2119-2126
Autor:
Zhang Ning, Takeshi Sano, Ryosuke Ikeuchi, Hideaki Takada, Kenji Nakamura, Toru Sakatani, Akihiro Hamada, Yuki Kita, Michiyuki Matsuda, Takashi Kobayashi
Publikováno v:
Journal of Urology. 209
Autor:
Shusuke Akamatsu, Hideaki Takada, Ryoichi Saito, Takayuki Goto, Akihiro Hamada, Toru Sakatani, Takeshi Sano, Yuki Kita, Kei Mizuno, Keiyu Matsumoto, Osamu Ogawa, Kenji Nakamura, Takashi Kobayashi, Tatsuaki Tsuruyama, Kaoru Murakami
Publikováno v:
Cancer Science
Overcoming cisplatin (CDDP) resistance is a major issue in urothelial cancer (UC), in which CDDP‐based chemotherapy is the first‐line treatment. WEE1, a G2/M checkpoint kinase, confers chemoresistance in response to genotoxic agents. However, the
Autor:
Yuki Kita, Takayuki Sumiyoshi, Takeshi Sano, Akihiro Hamada, Toru Sakatani, Kenji Nakamura, Hideaki Takada, Ryousuke Ikeuchi, Takayuki Goto, Atsuro Sawada, Shusuke Akamatsu, Takashi Kobayashi
Publikováno v:
Cancer Research. 83:235-235
Purpose: Genomic profiling in urothelial carcinoma (UC) conventionally uses tissue DNA. However, tissue biopsy is so invasive that it can be difficult in some cases. Cell-free DNA (cfDNA) assay is a minimally invasive tool obtaining a comprehensive g
Autor:
Keiyu Matsumoto, Shusuke Akamatsu, Yoshiyuki Matsui, Takeshi Sano, Osamu Ogawa, Takashi Kobayashi, Akihiro Hamada, Toru Sakatani, Kenji Nakamura, Atsuro Sawada
Publikováno v:
In Vivo
Background/aim Standard chemotherapy for advanced urothelial carcinoma (UC) patients with moderate renal dysfunction has not yet been established. Patients and methods We retrospectively assessed outcomes of patients with advanced UC who underwent fi
Autor:
Akihiro Hamada, Takeshi Sano, Yuki Kita, Hideaki Takada, Toru Sakatani, Kenji Nakamura, Katsuhiro Ito, Takayuki Goto, Atsuro Sawada, Shusuke Akamatsu, Takashi Kobayashi
Publikováno v:
Urologic oncology. 40(12)
To investigate the correlation between tumor size changes during the initial 4 cycles of first-line chemotherapy and tumor shrinkage following 2 additional cycles of chemotherapy in patients with advanced urothelial carcinoma (aUC) who experienced di
Publikováno v:
Pflugers Archiv
Serotonin (5-hydroxytryptamine [5-HT]) synthesized and released in enterochromaffin (EC) cells participates in various functions in the gastrointestinal tract by acting on a diverse range of 5-HT receptors (HTRs) expressed on smooth muscle, enteric n
Autor:
Masanao Koeda, Naoya Maeda, Akihiro Hamada, Atsuro Sawada, Toshihiro Magaribuchi, Osamu Ogawa, Katsuhiko Onishi, Hiroshi Noborio
Publikováno v:
Human-Computer Interaction. Technological Innovation ISBN: 9783031054082
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6fd7448ff25fcd2bc3b4728c308bbc4
https://doi.org/10.1007/978-3-031-05409-9_5
https://doi.org/10.1007/978-3-031-05409-9_5
Autor:
Toru Sakatani, Yuki Kita, Masakazu Fujimoto, Takeshi Sano, Akihiro Hamada, Kenji Nakamura, Hideaki Takada, Takayuki Goto, Atsuro Sawada, Shusuke Akamatsu, Takashi Kobayashi
Publikováno v:
Cancers
Cancers, Vol 14, Iss 263, p 263 (2022)
Cancers; Volume 14; Issue 2; Pages: 263
Cancers, Vol 14, Iss 263, p 263 (2022)
Cancers; Volume 14; Issue 2; Pages: 263
Simple Summary Pembrolizumab, an immune checkpoint inhibitor, has shown therapeutic benefit for advanced urothelial carcinoma (aUC) patients, but only a limited population achieves a long-term response. Prediction of treatment outcomes for aUC patien